The U.S. Food and Drug Administration has approved the first gene therapy for the treatment of ambulatory pediatric patients with Duchenne muscular dystrophy (DMD).
The recombinant gene therapy Elevidys is applicable to chldren in the age group of 4 to 5 having this disease with a confirmed mutation in the DMD gene who do not have a pre-existing medical reason preventing treatment with this therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.